Meta Pixel

News and Announcements

MadPaws nominated Disruptor of the Year

  • Published March 06, 2019 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Highlights

  • Mad Paws is the newest shared economy to hit the market, for your pets.
  • They offer a more personalised and economical alternative to kennels for pet owners.
  • Mad Paws nominated for Disruptor of the Year at the Mumbrella Travel Marketing Awards with winners announced in April.

With the infiltration of new shared economies hitting the market on a daily basis, it is a feat in itself to stand out. Mad Paws is the newest shared economy to hit the market, for your pets.

Paul and Cynthia from Mad Paws are making a living from one of their favourite hobbies – walking dogs. With kennels costs becoming out of reach for many dog owners, Mad Paws offer a more personalised and economical alternative for pet owners. At just $30 a night, your pooch can be walked, fed and playedwithinn the company of other dogs.

Their innovative new business has helped Paul and Cynthia earn over $1000 a month and have been nominated for Disruptor of the Year at the Mumbrella Travel Marketing Awards. Winners will be announced at the Mumbrella Travel Marketing Summit in Sydney on April 11.

 

About Mad Paws

Mad Paws, Australia’s largest Pet Sitting marketplace, connects Pet Owners with 15,000 local, vetted, and insured Pet Sitters and Dog Walkers. Mad Paws has scaled rapidly across Australia and is a proud partner of Qantas, who is also an investor alongside Equity Venture Partners and Macdoch Ventures.

The majority of the open investment round has been committed by existing shareholders. We would like to open up the remainder to new investors who share our vision.

Register Interest

Capital Insights
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship

From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now